10-Q quarterly report · filed Nov 10, 2026

Humacyte, Inc. (HUMA) Q3 2026 10-Q Quarterly Report

Short answer

Humacyte, Inc. (HUMA) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1M (up 36.5% year over year) with net income of −$16M.

Q3 2026 key financials · XBRL

Revenue
$1M
+36.5% YoY · +153.2% QoQ
Net income
−$16M
+11.3% YoY · +57.8% QoQ
Operating margin
-2287.8%
EPS (diluted)
−$0.05
+58.3% YoY · +68.8% QoQ

Source: XBRL data from the Humacyte, Inc. (HUMA) Q3 2026 10-Q on SEC EDGAR. USD.

Humacyte, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $1.0M, up from $0.8M YoY, driven by Symvess product sales
  • Operating loss $23.5M vs $24.4M YoY, operating margin -2,288.3% vs -3,048.8%
  • Symvess product revenue $1.0M vs $0.7M, the only reported product line
  • Cash, equivalents and restricted cash $64.9M, up from $19.8M; operating cash use $62.1M vs $78.9M
  • Going-concern risk, insufficient liquidity beyond one year without higher Symvess sales or additional capital

Risk Factors

  • Cost-saving execution risk: May 2026 workforce reduction of approximately 45 employees
  • Nasdaq compliance risk: $1.00 bid-price requirement, with compliance deadline January 27, 2027
  • Delisting financing risk: Nasdaq removal could impair liquidity and capital-raising ability
  • Workforce disruption risk: severance costs could negatively impact cash flows
  • Talent retention risk: unplanned attrition could reduce productivity and organizational knowledge

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Humacyte, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.